medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 1

<< Back Next >>

Med Int Mex 2018; 34 (1)

Update on the prescription of fluoroquinolones

Carrillo-Alduenda JL, Flores-Murrieta FJ, Rodríguez-Alcocer AN

Language: Spanish
References: 34
Page: 89-105
PDF size: 370.89 Kb.


ABSTRACT

Quinolones or fluoroquinolones are a group of commonly prescribed and broad-spectrum antibiotics drugs that act by inhibiting the enzymes responsible for the bacterial DNA replication, transcription, repair and recombination. The aim of this article is to present a systematic review of the three most representative fluoroquinolones in our country (ciprofloxacin, levofloxacin and moxifloxacin) in their three authorized indications: lower respiratory tract infections, urinary tract infections, skin and soft tissues infections.


REFERENCES

  1. Oliphant CM, Green GM. Quinolones: A comprehensive review. Am Fam Physician 2002;65:455-64.

  2. Scheld WM. Maintaining fluoroquinolone class efficacy: Review of influencing factors. Emerg Infect Dis 2003;9(1):1-9.

  3. Essential Medicines and Health Products Information Portal Ginebra, Organización Mundial de la Salud, 1999, actualizado el 2 de noviembre de 2016, (citado el 5 de diciembre de 2016), Disponible en http://apps.who.int/ medicinedocs/en/d/Jh1461e/5.8.html

  4. Gatifloxacin (marketed as Tequin) Information. Estados Unidos de América, Food and Drug Administration (FDA) actualizado 17 de mayo de 2015 (citado el 27 de marzo de 2017). Disponible en: https://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ ucm107821.htm

  5. Consulta de registros sanitarios México, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), 7 de octubre de 2016 (citado el 5 de diciembre de 2016)

  6. Galan Herrera JF, Poo JL, Rosales Sánchez O, et al. Bioavailability of two oral formulations of a single dose of levofloxacin 500 mg: An open-label, randomized, two-period crossover comparison in healthy Mexican volunteers. Clin Ther 2009;31:1796-1803.

  7. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44(10):2600-2603.

  8. Lomaestro BM, Bailie GR. Absorption interactions with fluoroquinolones. 1995 update. Drug Saf 1995;12(5):314-33.

  9. Mendoza Tamayo G, Rosete Reyes A, Medina Santillán R, et al. Bioavailability of two tablet formulations of a single dose of moxifloxacin 400 mg: An open-label, randomized, two-period crossover comparison in healthy Mexican adult volunteers. J Bioequiv Availab 2014;6(6):197-201.

  10. Zhanel GG, Walkty A, Vercaigne L, et al. The new fluoroquinolones: A critical review. Can J Infect Dis 1999;10(3):207- 238.

  11. Shah A, Lettieri L, Blum R, et al. Pharmacokinetics of intravenous ciprofloxacin in normal and renally impaired subjects. J Antimicrob Chemother 1996;38:103-116.

  12. Levaquin, multiple routes and forms. Estados Unidos de América, Food and Drug Administration (FDA) actualizado 5 de diciembre de 2016 (citado el 20 de diciembre de 2016), disponible en: http://www.accessdata.fda.gov/ drugsatfda_docs/label/2008/021721s020_020635s57_0 20634s52_lbl.pdf

  13. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones focus on respiratory tract infections. Drugs 2002;62(1):13-59.

  14. Cipro tablets. (Internet) Estados Unidos de América, Food and Drug Administration (FDA) actualizado 5 de diciembre de 2016 (citado el 5 de diciembre de 2016), disponible en: http://www.fda.gov/downloads/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/UCM130802. pdfhttp://www.fda.gov/downloads/Drugs/EmergencyPreparedness/ BioterrorismandDrugPreparedness/ UCM130802.pdfhttp://www.fda.gov/downloads/Drugs/ EmergencyPreparedness/BioterrorismandDrugPreparedness/ UCM130802.pdf

  15. Avelox, IV, Tablets 400 mg. Estados Unidos de América, Food and Drug Administration (FDA) actualizado 5 de diciembre de 2016 (citado el 20 de diciembre de 2016), disponible en: http://www.accessdata.fda.gov/drugsatfda_ docs/label/2008/021085s039,021277s033lbl.pdf

  16. Guidelines on Urological infections European Association of Urology, actualizado en marzo de 2015, (citado el 29 de diciembre de 2016) disponible en: https://uroweb. org/wp-content/uploads/18_Urological-infections_LR.pdf

  17. The Johns Hopkins Hospital. Antibiotic Guidelines 2015- 2016. 2015,

  18. Ortega-Romeroa M, Sorianoa A. Efectos adversos de las fluoroquinolonas. Med Integr 2000;36:396-9.

  19. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016;1-51.

  20. Guía de Práctica Clínica Prevención, Diagnóstico y Tratamiento de la Neumonía Adquirida en la Comunidad en Adultos; Instituto Mexicano del Seguro Social, 2009;36.

  21. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Clin Microbiol Infect 2011;17:6:E1-E59.

  22. Guía de práctica clínica. Diagnóstico y tratamiento de la enfermedad pulmonar obstructiva. México: Secretaría de Salud, 2009.

  23. Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015;372(14):1312-23.

  24. Moss PJ, Finch RG. The next generation: fluoroquinolones in the management of acute lower respiratory infection in adults. Thorax 2000;55(1):83-5.

  25. Smith HJ, Nichol KA, Hoban DJ, Zhanel GG. Dual activity of fluoroquinolones against Streptococcus pneumoniae: the facts behind the claims. J Antimicrob Chemother 2002;49(6):893-5.

  26. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit a proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000:162:505-511.

  27. Gutiérrez-Castrellón P, Díaz-García L, de Colsa-Ranero A, et al. Efficacy and safety of ciprofloxacin treatment in urinary tract infections (UTIs) in adults: a systematic review with meta-analysis. Gac Méd Méx 2015;151(2):225-44.

  28. Dielubanza EJ, Schaeffer AJ. Urinary tract infections in women. Med Clin North Am 2011;95(1):27-41.

  29. Drekonja DM, Johnson JR. Urinary tract infections. Prim Care 2008 Jun;35(2):345-67.

  30. Stevens D, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis 2014:59:e10-e52.

  31. Castro G, Liceaga G, Arrioja A, et al. Guía clínica basada en evidencia para el manejo del pie diabético. Med Int Méx 2009;25(6):481-526.

  32. Majcher-Peszynska J, Sass M, Schipper S, et al. Pharmacokinetics and penetration of moxifloxacin into infected diabetic foot tissue in a large diabetic patient cohort. Eur J Clin Pharmacol 2011;67(2):135-42.

  33. Bradley JS, Jackson MA, et al. Clinical report, The use of systemic and topical fluoroquinolones. Pediatrics 2011;128:4. e1034-e1045.

  34. Grupo de trabajo sobre niveles de evidencia del OCEBM*. Niveles de evidencia 2011 de Oxford (The Oxford 2011 Levels of Evidence). Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/index.aspx?o=5653.




2020     |     www.medigraphic.com